文献速递帕金森病与运动障碍

通过激励生物标志物预测帕金森病冲动控制障碍

Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers.
PubMed 文献 · Ann Neurol · 2022-09-09

本研究为纵向队列,纳入无冲动控制障碍(ICD)病史的非痴呆帕金森病患者,记录赌博任务中的反馈相关负波(FRN),并进行30个月前瞻性随访。基线FRNdiff在后来发生ICD的患者中更大(-2.33μV vs -0.84μV,p=0.001),且与ICD发生显著相关(未调整HR=0.73,95%CI 0.58-0.91,p=0.006;调整后HR=0.74,95%CI 0.55-0.97,p=0.035)。

要点

  • 基线FRNdiff在发生ICD的患者中更大(-2.33μV vs -0.84μV,p=0.001)。
  • FRNdiff与ICD发生显著相关,未调整HR=0.73(95%CI 0.58-0.91,p=0.006)。
  • 调整多巴胺替代治疗、性别和年龄后HR=0.74(95%CI 0.55-0.97,p=0.035)。

核心结论

  • FRN信号所测量的奖赏处理差异先于帕金森病ICD的发生,该神经生理标志物可识别ICD发生高风险的患者。

研究设计与样本

  • 纵向队列研究,纳入连续的非痴呆且无ICD病史的帕金森病患者;2015年10月7日至2016年12月16日筛查120例,94例完成赌博任务,92例完成随访;进行30个月的前瞻性每半年随访评估以检测新发ICD。

主要发现

  • 随访期间18例发生ICD,74例未发生ICD。
  • 基线FRNdiff在发生ICD的患者中大于未发生ICD的患者(-2.33μV vs -0.84μV,p=0.001)。
  • 未发现其他显著的基线差异。
  • FRNdiff与ICD发生在生存模型中显著相关:未调整HR=0.73(95%CI 0.58-0.91,p=0.006),控制多巴胺替代治疗、性别和年龄后HR=0.74(95%CI 0.55-0.97,p=0.035)。
  • 所评估的冲动性测量指标均与ICD发生无关。

临床怎么用

  • 作者认为FRN信号所测量的奖赏处理差异先于帕金森病ICD发生,该神经生理标志物可识别ICD发生高风险的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disorders (ICDs) in Parkinson disease (PD). METHODS: The longitudinal cohort consisted of consecutive nondemented PD patients with no ICD history. We recorded FRN signals while they performed a gambling task. We calculated the mean amplitude difference between losses and gains (FRNdiff) to be used as a predictor of future ICD development. We performed prospective biannual follow-up assessments for 30 months to detect incident ICDs. Finally, we evaluated how basal FRNdiff was associated with posterior development of ICDs using survival models. RESULTS: Between October 7, 2015 and December 16, 2016, we screened 120 patients. Among them, 94 patients performed the gambling and 92 completed the follow-up. Eighteen patients developed ICDs during follow-up, whereas 74 remained free of ICDs. Baseline FRNdiff was greater in patients who developed ICDs than in those who did not (-2.33μV vs -0.84μV, p = 0.001). No other significant baseline differences were found. The FRNdiff was significantly associated with ICD development in the survival models both when not adjusted (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.58-0.91, p = 0.006) and when controlling for dopamine replacement therapy, sex, and age (HR = 0.74, 95% CI = 0.55-0.97, p = 0.035). None of the impulsivity measures evaluated was related to ICD development. INTERPRETATION: Reward-processing differences measured by FRN signals precede ICD development in PD. This neurophysiological marker permits identification of patients with high risk of ICD development. ANN NEUROL 2022;92:974-984.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Marín-Lahoz J, Martinez-Horta S, Pagonabarraga J, et al. Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers. Ann Neurol. 2022. PMID: 36054656. doi:10.1002/ana.26486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。